2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Cytoskeleton
    Stem Cell/Wnt
    TGF-beta/Smad
  4. ROCK
  5. ROCK2 Isoform

ROCK2

ROCK2 (Rho-associated coiled-coil-containing protein kinase 2) is a serine/threonine kinase that functions as a major downstream effector of Rho GTPases and regulates cytokinesis, smooth muscle contraction, actin stress fiber formation, focal adhesion dynamics, and transcriptional responses linked to cytoskeletal remodeling[1][2]. Mechanistically, ROCK2 promotes actomyosin contractility through signaling networks that control actin organization, cell morphology, migration, proliferation, adhesion, and inflammatory responses, placing it at the center of cytoskeleton-dependent cellular regulation[3][6]. Because these processes govern tissue homeostasis and cellular adaptation, dysregulated ROCK signaling has been implicated in cardiovascular, neurodegenerative, inflammatory, and cancer-associated pathologies[3][4]. In experimental disease models, ROCK2 has been identified as an important regulator of neuronal survival, axonal stability after injury, and regenerative responses, supporting its utility for studying neurodegeneration and neural repair mechanisms[5]. Compared with the closely related isoform ROCK1, ROCK2 shares high homology within the kinase domain but exhibits distinct tissue distribution and isoform-specific biological functions, highlighting the importance of discriminating ROCK2-dependent signaling from broader ROCK activity in mechanistic studies[3][4]. For experimental applications, pharmacological inhibition of ROCK signaling is widely used to interrogate cytoskeletal regulation and disease-associated pathways, and the development of isoform-selective inhibitors has increased interest in defining ROCK2-specific functions with greater precision[4]>.

ROCK2 Related Products (70):

Cat. No. Product Name Effect Purity
  • HY-10071
    Y-27632
    		Inhibitor 99.91%
    Y-27632 is a ROCK inhibitor with Ki values of 220 nM and 300 nM for ROCK1 and ROCK2, respectively. Y-27632 exerts anti-inflammatory and immunomodulatory effects in systemic lupus erythematosus models by inhibiting the ROCK/NF-κB pathway. Y-27632 enhances autophagy by inhibiting the AKT/mTOR pathway, thereby inducing apoptosis apoptosis in oral squamous cell carcinoma. Y-27632 induces the formation of tunneling nanotubes in ARPE-19 cells and significantly enhances mitochondrial transfer through these channels. Y-27632 promotes neurite outgrowth in PC12 cells by activating the Rac1/NOX1/ROS/AKT/PAK1 signaling cascade.
  • HY-10583
    Y-27632 dihydrochloride
    		Inhibitor 99.98%
    Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I Ki=220 nM; ROCK-II Ki=300 nM). Y-27632 dihydrochloride shows antiepileptic effects.
  • HY-15392
    Chroman 1
    		Inhibitor 98.97%
    Chroman 1 is a highly potent and selective ROCK inhibitor. Chroman 1 is more potent against ROCK2 (IC50=1 pM) than ROCK1 (IC50=52 pM). Chroman 1 also has inhibitory activity against MRCK, with an IC50 of 150 nM.
  • HY-10341
    Fasudil Hydrochloride
    		Inhibitor 99.97%
    Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil Hydrochloride is also a potent Ca2+ channel antagonist and vasodilator.
  • HY-15307
    Belumosudil
    		Inhibitor 99.83%
    Belumosudil (KD025) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties.
  • HY-181582
    LASSBio-2382
    		Inhibitor
    LASSBio-2382 is a dual ROCK1/ROCK2 inhibitor with ROCK1 IC50 of 0.005 μM and ROCK2 IC50 of 0.003 μM. LASSBio-2382 inhibits viability and migration of cancer cells. LASSBio-2382 can be used for the research of triple-negative breast cancer.
  • HY-184149
    ROCK2-IN-17
    		Inhibitor
    ROCK2-IN-17 is an orally active and selective ROCK2 inhibitor with an IC50 of 8.1 nM. ROCK2-IN-17 achieves its antifibrotic effect by inhibiting the TGF-β/Smad and ROCK2/STAT3 signaling pathways. ROCK2-IN-17 can be used for pulmonary fibrosis research.
  • HY-185667
    ROCK2-IN-15
    		Inhibitor
    ROCK2-IN-15 (2-11) is a ROCK2 inhibitor with selective activity against Rho-kinase mediated phosphorylation of myosin light chain phosphates .ROCK2-IN-15 can be used for the research of cardiovascular diseases, pulmonary diseases, inflammatory diseases, neurological diseases, proliferative diseases .
  • HY-103045
    CMPD101
    		Inhibitor 98.96%
    CMPD101 is a potent, highly selective and membrane-permeable small-molecule inhibitor of GRK2/3 with IC50 of 18 nM and 5.4 nM, respectively. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC50s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively. CMPD101 can be used for the study of heart failure.
  • HY-15556
    GSK269962A
    		Inhibitor 99.75%
    GSK269962A (GSK 269962) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A has anti-inflammatory and vasodilatory activities.
  • HY-10341A
    Fasudil
    		Inhibitor 99.98%
    Fasudil (HA-1077; AT877) is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil is also a potent Ca2+ channel antagonist and vasodilator.
  • HY-15685
    Ripasudil
    		Inhibitor 99.95%
    Ripasudil (K-115) is a specific inhibitor of ROCK, with IC50s of 19 and 51 nM for ROCK2 and ROCK1, respectively.
  • HY-15307A
    Belumosudil mesylate
    		Inhibitor 99.89%
    Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 µM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties.
  • HY-15720A
    H-1152 dihydrochloride
    		Inhibitor 99.47%
    H-1152 dihydrochloride is a membrane-permeable and selective ROCK inhibitor, with a Ki value of 1.6 nM, and an IC50 value of 12 nM for ROCK2.
  • HY-119937
    ROCK inhibitor-2
    		Inhibitor 99.92%
    ROCK inhibitor-2 (compound 6) is a selective dual inhibitor of ROCK1 and ROCK2, with IC50 values of 160 nM and 21 nM, respectively. ROCK inhibitor-2 inhibits pMYPT1 with IC50 of 75 nM. ROCK inhibitor-2 exhibits antitumor activity.
  • HY-15755
    RKI-1447
    		Inhibitor 98.02%
    RKI-1447 is a potent small molecule inhibitor of ROCK1 and ROCK2 with IC50 values of 14.5 nM and 6.2 nM, respectively.
  • HY-15720
    H-1152
    		Inhibitor 99.00%
    H-1152 is a membrane-permeable and selective ROCK inhibitor, with a Ki value of 1.6 nM, and an IC50 value of 12 nM for ROCK2.
  • HY-13300
    SR-3677
    		Inhibitor 99.83%
    SR-3677 is a potent and selective ROCK-II inhibitor with an IC50 of ~3 nM.
  • HY-15687A
    SAR407899
    		Inhibitor 99.67%
    SAR407899 is a selective, potent and ATP-competitive ROCK inhibitor, with an IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and rat ROCK-2, respectively. SAR407899 shows stable inhibition of migrasome formation.
  • HY-18713
    CRT0066854
    		Inhibitor 99.54%
    CRT0066854 is a potent and selective atypical PKC isoenzymes inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively.
Cat. No. Product Name / Synonyms Application Reactivity